The World Health Organization's Emergency Committee met for the second time on August 18 to reassess the Bundibugyo virus disease outbreak in the Democratic Republic of Congo, and the temporary recommendations it issued afterward contain a sentence easy to miss in the coverage that followed: "Unlike Ebola virus causing Ebola virus disease, although clinical trials are ongoing, there are no currently approved therapeutics or vaccines against BDBV." [1] That single clause does most of the work this story needs to do. This is not the Ebola-Zaire strain that has an approved vaccine deployed in prior West and Central African outbreaks. It is Bundibugyo virus, a distinct strain within the same genus, and against it, medicine currently has nothing licensed to offer.
WHO's language is careful in a way headline writing often is not. The committee's text notes that should effective vaccines eventually become available for this specific strain, they are "likely to have a complementary effect on transmission and mortality" based on experience from the 2013-2016 West African Ebola epidemic — but explicitly adds that they "will not be a substitute for effective, core public health interventions." [1] That is a scientific body managing expectations in real time, aware that "vaccine" is a word readers hear as "solution," and trying to head off exactly that inference before it spreads faster than the virus itself.
This paper flagged the shape of that problem a month ago. When Singapore's Hilleman Laboratories announced it would advance the WHO-designated most-promising Bundibugyo vaccine candidate toward human trials, this paper's account was explicit that a candidate moving toward trials is not a trial start, not a result, and not a dose anywhere near the outbreak zone. That distinction has only sharpened since. WHO's August 24 recommendations confirm formally what was implicit a month ago: the candidate remains in the trial pipeline, not in a syringe, and the outbreak that has driven the region's death toll into record territory is still being fought entirely with the tools medicine had before this strain had a name recognized by international regulators.
Those tools are what the bulk of WHO's new guidance is actually about. The recommendations, assessed for a "very high" risk country as of August 14 — currently only the DRC — run through surveillance, contact tracing, safe burial protocols, infection control in health facilities, and a newly added section on social measures: postponing mass gatherings in transmission areas, limiting motorbike passengers to one per vehicle, and establishing round-the-clock health checkpoints on roads connecting affected zones to the rest of the country. [1] Nine neighboring states — Angola, Burundi, the Central African Republic, the Republic of Congo, Rwanda, South Sudan, Tanzania, Uganda and Zambia — are classified at "high" risk and told to strengthen border surveillance and readiness, but WHO explicitly does not recommend suspending flights or denying entry to travelers from affected areas. [1]
The gap between what outbreak coverage often implies and what WHO's own text says is not a matter of malice or fabrication; it is the ordinary slippage between "a vaccine candidate exists" and "a vaccine exists." For a strain driving deaths at a pace outrunning containment measures, that slippage matters more than usual. Readers who come away from headline shorthand believing help is closer than it is may misjudge both the urgency of the outbreak and the actual timeline for anything resembling relief.
-- KENJI NAKAMURA, Tokyo